A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC, Rosenberg BJ, Sekine-Konno T, Varma P, Chen K, Koleske AJ, Reiman EM, Strittmatter SM, van Dyck CH. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimer's Research & Therapy 2015, 7: 35. PMID: 25874001, PMCID: PMC4396171, DOI: 10.1186/s13195-015-0119-0.Peer-Reviewed Original ResearchRegional cerebral glucose metabolismCerebral glucose metabolismTreatment of patientsClinical efficacy measuresModerate Alzheimer's diseaseAlzheimer's diseaseEfficacy measuresGlucose metabolismCentral nervous system availabilityMultiple ascending dose studyFluorodeoxyglucose positron emission tomographyPhase IIa clinical trialMini-Mental State Examination scoreCentral nervous system penetrationPromising new therapeutic targetCSF drug levelsMultiple ascending doseOligomeric amyloid betaPhase Ib trialPlacebo-controlled trialAscending dose studyCongestive heart failureCerebrospinal fluid penetrationDisease-modifying therapiesIIa clinical trial